HIMS's multi-pronged build-out (AI, preventive care and peptides) is starting to work together, and the FDA peptide advi
HIMS's multi-pronged build-out (AI, preventive care and peptides) is starting to work together, and the FDA peptide advisory committee review on 23-24 Jul is the key near-term catalyst. The share price has already caught up with the analyst consensus target, so further upside depends on Q2 data or progress on peptides.
Analyst consensus
The consensus analyst price target is about $27-28. The current price has largely caught up with it, so further upside needs to be driven by Q2 data or progress on peptides.
Key insights
- Date
2026-06-05
- Detail
WeightWatchers Med+ offers GLP-1 drugs through Eli Lilly's LillyDirect platform, with behavioural coaching, nutrition management and clinical support. It adds to the competition on several fronts alongside Amazon Pharmacy and Ro, but WW is positioned more as support for behavioural intervention. It stays away from compounded drugs, peptides and diagnostic testing, which leaves room to differentiate from HIMS's full-stack platform.
- Item
WeightWatchers Med+ plugs into LillyDirect
- Date
2026-06-05
- Detail
The CEO said on X that Anthropic's AI is transformative for population health. Taken together with the launch of Labs AI (AI pattern recognition across 130+ biomarkers) and the remit of the new CMO Vinjamoori, which covers peptide therapies and longevity medicine, management is integrating the three lines of AI, preventive care and peptides.
- Item
CEO Dudum publicly backs Anthropic's AI
- Date
2026-06-05
- Detail
Canaccord Genuity estimates the total addressable market (TAM) for non-GLP-1 compounded peptides at about $20 billion over 3-5 years. Every 1% of share HIMS captures equals $200 million of incremental revenue. Its competitive advantages: the 2025 acquisition of a US peptide manufacturing facility, a 1 million square foot 503A compounding site, and brand trust.
- Item
Canaccord sizes the peptide market opportunity
Peptide catalyst
The FDA peptide advisory committee will review 12 peptides (including BPC-157 and TB-500) on 23-24 Jul, the most important near-term catalyst.
Price action
Closed at $28.01 on 5 Jun (up 2%), a second positive week in a row. On 6 Jun US stocks fell sharply (the Dow down 1.2% and semiconductors hit hard) and HIMS slipped about 1% after hours, but overall it is still holding steady in a $25-30 range.
Sources (1)
- LillyDirect / Dudum X post / Canaccord Genuity via TIKR / market data
A brief is a lead for our research, not a verified conclusion or advice.